Cite
MLA Citation
Rodney P. Rocconi et al.. “Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.” Obstetrical & gynecological survey, vol. 76, no. 3, 2021, pp. 151–152. http://access.bl.uk/ark:/81055/vdc_100145479519.0x000054